News

News

Wegovy Pill could rival injectables

08 Dec 2025
Novo Nordisk’s OASIS 4 phase 3 trial shows that a daily oral Wegovy pill could be a highly effective alternative to the injectable version. The 25mg oral semaglutide demonstrated significant improvements in blood sugar, blood pressure and cardiovascular risk, with the greatest benefits seen in patients who lost at least 15% of their body weight. Researchers highlight the drug’s ability to reduce “food noise” by mimicking the GLP-1 hormone, improving appetite control and metabolic regulation. While GLP-1 use is rising, experts warn against cosmetic, off-label use. The oral formulation is not yet approved by SAHPRA, with US review expected later this year.
[BACK TO NEWS]